NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

表纸
市场调查报告书

感染疾病相关的各种联盟契约:交易趋势、相关企业、财务条件

Global Infectious Diseases Partnering 2014-2020: Deal trends, players and financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品编码 246679
出版日期 内容资讯 英文 1400+ Pages
订单完成后即时交付
价格
感染疾病相关的各种联盟契约:交易趋势、相关企业、财务条件 Global Infectious Diseases Partnering 2014-2020: Deal trends, players and financials
出版日期: 2020年11月01日内容资讯: 英文 1400+ Pages
简介

本报告提供感染疾病相关的近几年的各种联盟契约的相关调查,进行近几年的趋势、趋势,活跃地联盟契约的企业,主要的大规模契约,各种联盟契约的交易额、契约类型、技术区分、协定内容、目的、条件等的各种资料汇整。

摘要整理

第1章 简介

第2章 感染疾病相关的各种契约趋势

  • 简介
  • 过去数年的感染疾病相关的联盟
  • 感染疾病相关的联盟:各类型契约
  • 感染疾病相关的联盟:各产品部门
  • 感染疾病相关的联盟:各开发阶段
  • 感染疾病相关的联盟:各技术类型
  • 感染疾病相关的联盟:各适应症

第3章 财务条件

  • 简介
  • 公开财务条件
  • 契约总额
  • 预付款金
  • 里程碑
  • 权利金费率

第4章 主要契约、契约经营者

  • 简介
  • 联盟活动最活跃的经营者
  • 主要契约经营者清单
  • 主要契约:各交易金额

第5章 契约文件目录

第6章 感染疾病相关合约:各治疗标的

  • 简介
  • 感染疾病相关合约:各治疗标的

附录

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: CP2206

Global Infectious Diseases Partnering 2014-2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the infectives partnering deals and agreements entered into by the worlds leading healthcare companies

Global Infectious Diseases Partnering 2014 to 2020 provides the full collection of Infectious Diseases disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Trends in Infectious Diseases partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Infectious Diseases partnering agreement structure

Infectious Diseases partnering contract documents

Top Infectious Diseases deals by value

Most active Infectious Diseases dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.

The report presents financial deal terms values for Infectious Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Infectious Diseases dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Infectious Diseases dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Infectious Diseases deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Infectious Diseases dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Infectious Diseases deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Infectious Diseases partnering deals by specific Infectious Diseases target announced since 2014. The chapter is organized by specific Infectious Diseases therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Infectious Diseases partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Diseases partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Diseases technologies and products.

Report scope

Global Infectious Diseases Partnering 2014 to 2020 is intended to provide the reader with an in-depth understanding and access to Infectious Diseases trends and structure of deals entered into by leading companies worldwide.

Global Infectious Diseases Partnering 2014 to 2020 includes:

  • Trends in Infectious Diseases dealmaking in the biopharma industry since 2014
  • Analysis of Infectious Diseases deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Infectious Diseases deal contract documents
  • Comprehensive access to over 2300 Infectious Diseases deal records
  • The leading Infectious Diseases deals by value since 2014
  • Most active Infectious Diseases dealmakers since 2014

The report includes deals for the following indications:

  • Bacterial: Anthrax, Campylobacter Jejuni, Clostridium difficile, Diphtheria, Escherichia Coli (E-coli), Group A Streptococcus, Group B Streptococcus, Haemophilus influenzae type b (Hib), Helicobacter Pylori, Lyme disease, Methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium avium, Pertussis (Whooping Cough), Pseudomonas aeruginosa, Salmonella, Sepsis, Tetanus, Tuberculosis (TB), plus other bacterial indications
  • Viral: Common cold, Cytomegalovirus, Ebola, FIV, Foot and mouth disease, Hepatitis A, B, C, D, Herpes simplex, HIV, Influenza, H5N1 (Avian Flu), H1N1 (Swine Flu), Japanese encephalitis, Polio, Respiratory syncytial virus (RSV), Zika, plus other viral indications.
  • Parasitic
  • Fungal: Nail Psoriasis, Onychomycosis (Nail infection), plus other fungal indications
  • Tropical: African trypanosomiasis (Sleeping sickness), Dengue fever, Malaria, West Nile Virus, Yellow fever, plus other tropical indications

In Global Infectious Diseases Partnering 2014 to 2020, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Infectious Diseases Partnering 2014-2020 report provides comprehensive access to available deals and contract documents for over 2,300 infectious diseases deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Infectious Diseases Partnering 2014 to 2020 provides the reader with the following key benefits:

  • In-depth understanding of Infectious Diseases deal trends since 2014
  • Access Infectious Diseases deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Infectious Diseases partner companies
  • Comprehensive access to over 2,300 links to actual Infectious Diseases deals entered into by the world's biopharma companies
  • Indepth review of Infectious Diseases deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Infectious Diseases opportunities
  • Uncover companies actively partnering Infectious Diseases opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Diseases dealmaking

  • 2.1. Introduction
  • 2.2. Infectious Diseases partnering over the years
  • 2.3. Infectious Diseases partnering by deal type
  • 2.4. Infectious Diseases partnering by industry sector
  • 2.5. Infectious Diseases partnering by stage of development
  • 2.6. Infectious Diseases partnering by technology type
  • 2.7. Infectious Diseases partnering by therapeutic indication

Chapter 3 -Financial deal terms for Infectious Diseases partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Infectious Diseases partnering
  • 3.3. Infectious Diseases partnering headline values
  • 3.4. Infectious Diseases deal upfront payments
  • 3.5. Infectious Diseases deal milestone payments
  • 3.6. Infectious Diseases royalty rates

Chapter 4 - Leading Infectious Diseases deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Infectious Diseases partnering
  • 4.3. List of most active dealmakers in Infectious Diseases
  • 4.4. Top Infectious Diseases deals by value

Chapter 5 - Infectious Diseases contract document directory

  • 5.1. Introduction
  • 5.2. Infectious Diseases partnering deals where contract document available

Chapter 6 - Infectious Diseases dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Infectious Diseases therapeutic target

Appendices

  • Appendix 1 - Directory of Infectious Diseases deals by company A-Z since 2014
  • Appendix 2 - Directory of Infectious Diseases deals by deal type since 2014
  • Appendix 3 - Directory of Infectious Diseases deals by stage of development since 2014
  • Appendix 4 - Directory of Infectious Diseases deals by technology type sinc 2014
  • Further reading on dealmaking
  • Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering
  • Table of figures
  • Figure 1: Infectious Diseases partnering since 2014
  • Figure 2: Infectious Diseases partnering by deal type since 2014
  • Figure 3: Infectious Diseases partnering by industry sector since 2014
  • Figure 4: Infectious Diseases partnering by stage of development since 2014
  • Figure 5: Infectious Diseases partnering by technology type since 2014
  • Figure 6: Infectious Diseases partnering by indication since 2014
  • Figure 7: Infectious Diseases deals with a headline value
  • Figure 8: Infectious Diseases deals with upfront payment values
  • Figure 9: Infectious Diseases deals with milestone payment
  • Figure 10: Infectious Diseases deals with royalty rates
  • Figure 11: Active Infectious Diseases dealmaking activity since 2014
  • Figure 12: Top Infectious Diseases deals by value since 2014